Overview
SNAP-8 (acetyl octapeptide-3, INCI: Acetyl Glutamyl Heptapeptide-1) is a synthetic peptide developed by Lipotec as an extension of their earlier hexapeptide Argireline® (acetyl hexapeptide-3). Consisting of 8 amino acids with an N-terminal acetyl group, SNAP-8 was designed to inhibit the SNARE complex formation required for neuromuscular vesicle fusion, effectively reducing the intensity of facial muscle contractions that create expression lines.
The SNARE (Soluble N-ethylmaleimide-sensitive factor Attachment protein REceptor) complex is the molecular machinery that enables neurotransmitter release at the neuromuscular junction. By competitively binding components of this complex, SNAP-8 reduces acetylcholine release without completely paralyzing the muscle, offering a 'Botox-lite' effect that softens rather than eliminates facial expression.
SNAP-8 represents the peptide cosmeceutical industry's most advanced topical approach to wrinkle reduction through neuromuscular modulation. Unlike botulinum toxin, which requires precise injection by a skilled practitioner, SNAP-8 can be incorporated into daily skincare formulations and applied non-invasively, making it accessible for consumer-level anti-aging protocols.
While in vitro data is compelling, the clinical evidence for topical peptide neuromuscular modulation remains debated, as the stratum corneum presents a significant barrier to peptide penetration. Advanced delivery systems including liposomes, nanoparticles, and penetration enhancers are being developed to improve dermal bioavailability.
Quick facts
- Mechanism
- SNARE complex inhibitor reducing facial muscle contraction intensity
- Primary use
- Anti-Wrinkle & Cosmetic Anti-Aging
- Evidence
- moderate
- FDA
- Not approved
- Route
- Topical application
- Typical results
- Clinical studies show 35–63% reduction in wrinkle depth with topical application over 28 days
Chemical information
SNAP-8 (C₄₂H₇₂N₁₆O₁₅S) is a tissue remodeling compound with a molecular weight of 1073.2 g/mol. Its structural characteristics underpin its biological activity in tissue remodeling and structural repair.
How SNAP-8 works
SNAP-8 acts as a competitive inhibitor of SNAP-25 (synaptosomal-associated protein 25 kDa), one of three proteins forming the SNARE complex required for synaptic vesicle fusion at the neuromuscular junction. By occupying SNAP-25 binding sites, SNAP-8 destabilizes the ternary SNARE complex (SNAP-25 + Syntaxin-1 + VAMP/Synaptobrevin), reducing the efficiency of acetylcholine release and moderating muscle contraction intensity.
The SNARE complex assembly follows a precise molecular zipper mechanism where SNAP-25 provides two α-helical domains that interact with one helix from syntaxin-1a and one from VAMP-2 to form a four-helix bundle. This bundle generates the mechanical force required to overcome the energy barrier for membrane fusion. SNAP-8's N-terminal sequence mimics the SNAP-25 N-terminal domain, competitively displacing endogenous SNAP-25 and producing incomplete SNARE complexes incapable of efficient vesicle fusion.
In vitro studies using chromaffin cell models showed that SNAP-8 reduced catecholamine release by approximately 63% at a concentration of 150 μM, demonstrating significant neurotransmitter release inhibition. This effect is dose-dependent and reversible, meaning that SNAP-8 modulates rather than eliminates neuromuscular transmission.
The topical efficacy of SNAP-8 depends critically on dermal penetration. The peptide's molecular weight (1073.2 g/mol) and hydrophilic character present challenges for stratum corneum permeation. Modern formulations address this using lipid nanoparticle carriers, chemical penetration enhancers (e.g., DMSO derivatives), and iontophoretic delivery systems to achieve therapeutic concentrations in the dermis.
- SNAP-25 competition: Displaces endogenous SNAP-25 from the SNARE ternary complex
- Vesicle fusion inhibition: Destabilizes the four-helix bundle needed for membrane fusion
- Neurotransmitter reduction: Decreases acetylcholine release at the neuromuscular junction by up to 63%
- Reversible modulation: Softens muscle contraction without paralysis, preserving expression
- Topical delivery: Non-invasive application when formulated with appropriate penetration systems
Pharmacokinetics
| Parameter | Value | Significance |
|---|---|---|
| Molecular Weight | 1073.2 g/mol | Large for topical penetration; requires formulation optimization |
| Solubility | Water-soluble | Compatible with aqueous serum formulations |
| Optimal Concentration | 3–10% in formulation | Dose-dependent efficacy demonstrated in clinical studies |
| Onset of Effect | 7–28 days | Gradual wrinkle reduction with consistent daily application |
Dosing & administration
SNAP-8 dosing varies by indication and individual factors. No FDA-approved dosing exists for this compound; protocols in the literature derive from limited clinical or preclinical data and practitioner experience.
Any use should be conducted under qualified medical supervision with appropriate monitoring of safety markers.
Important: These dosing ranges are not FDA-approved. Any use should be under qualified medical supervision.
Side effects & safety
Safety data for SNAP-8 is primarily derived from preclinical studies and limited human data. Long-term effects in humans remain incompletely characterized.
Common
- • Non-invasive topical alternative to botulinum toxin injections
- • 35–63% reduction in wrinkle depth in clinical assessments
- • Preserves natural facial expression while softening lines
- • Can be combined with other active skincare ingredients
- • No injection pain, bruising, or practitioner requirement
- • Suitable for daily preventative anti-aging use
Serious / potential risks
- • Generally well-tolerated topically
- • Mild skin irritation in sensitive individuals (rare)
- • Efficacy limited by stratum corneum penetration
- • No systemic side effects expected from topical use
- • May require advanced delivery formulations for optimal results
Drug interactions
| Medication | Interaction | Recommendation |
|---|---|---|
| Botulinum toxin (Botox) | Additive neuromuscular inhibition | Can complement Botox between injection cycles; may extend time between treatments |
| Retinoids (Tretinoin) | Enhanced penetration | Retinoids disrupt stratum corneum; may increase SNAP-8 delivery but also irritation risk |
| AHA/BHA exfoliants | Improved absorption | Chemical exfoliation may enhance peptide penetration; use sequentially, not simultaneously |
| Other cosmetic peptides (GHK-Cu, AHK-Cu) | Complementary | Different mechanisms; can be combined for multi-target anti-aging approach |
Storage & handling
Lyophilized (powder)
- • Store at -20°C to 4°C (freezer or refrigerator)
- • Protect from light and moisture
- • Stable for 12–24 months when stored properly
- • Keep in original sealed container until reconstitution
Reconstituted solution
- • Refrigerate at 2–8°C after reconstitution
- • Use bacteriostatic water for multi-dose reconstitution
- • Typical stability: 14–28 days refrigerated
- • Do not freeze reconstituted solution
Cost & availability
| Source | Cost | Notes |
|---|---|---|
| Research suppliers | Varies widely | Quality and purity vary significantly between sources |
| Compounding pharmacies | Prescription required | Higher quality assurance and purity testing |
The bottom line
SNAP-8 is a tissue remodeling compound with research interest in anti-wrinkle, snare complex, cosmetic peptide. While preclinical evidence is encouraging, it remains investigational and is not FDA-approved. Any use should be under qualified medical supervision.
Best for
- • Researchers studying tissue remodeling and structural repair
- • Individuals interested in anti-wrinkle under medical guidance
Not for
- • Self-administration without medical supervision
- • Pregnant or breastfeeding individuals
- • Individuals with contraindicated conditions
Related compounds
Frequently asked questions
References
- [1] Lipotec Active Ingredients.. SNAP-8: A second-generation anti-wrinkle octapeptide. Lipotec Technical Dossier (2005).
- [2] Blanes-Mira C, Clemente J, Jodas G, et al.. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci (2002). doi: 10.1046/j.1467-2494.2002.00146.x PMID: 18498517
- [3] Zhang L, Falla TJ.. Cosmeceuticals and peptides. Clin Dermatol (2009). doi: 10.1016/j.clindermatol.2008.01.012 PMID: 19168000
- [4] Schagen SK.. Topical peptide treatments with effective anti-aging results. Cosmetics (2017). doi: 10.3390/cosmetics4020016